Although the human pathological model is certainly more complex than that described here (for example, by including marked pro-inflammatory issues), PDE-5 inhibition may become an appreciable target for long-term treatment of pulmonary hypertension, and perhaps also for the prevention of this debilitating disease. Here, PDE5A is linked to pulmonary arterial hypertension.